Cargando…

Enhanced Inhibition of Prostate Tumor Growth by Dual Targeting the Androgen Receptor and the Regulatory Subunit Type Iα of Protein Kinase A in Vivo

Progression to castration resistance is a major problem in the treatment of advanced prostate cancer and is likely to be driven by activation of several molecular pathways, including androgen receptor (AR) and cyclic AMP-dependent protein kinase A (PKA). In this study, we examined the therapeutic ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eder, Iris E., Egger, Martina, Neuwirt, Hannes, Seifarth, Christof, Maddalo, Danilo, Desiniotis, Andreas, Schäfer, Georg, Puhr, Martin, Bektic, Jasmin, Cato, Andrew C. B., Klocker, Helmut
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Molecular Diversity Preservation International (MDPI) 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709765/ https://www.ncbi.nlm.nih.gov/pubmed/23736698 http://dx.doi.org/10.3390/ijms140611942

Ejemplares similares

Cancer-Associated Fibroblasts Modify the Response of Prostate Cancer Cells to Androgen and Anti-Androgens in Three-Dimensional Spheroid Culture
por: Eder, Theresa, et al.
Publicado: (2016)

PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells
por: Puhr, Martin, et al.
Publicado: (2014)

Reduced Levels of ATP Synthase Subunit ATP5F1A Correlate with Earlier-Onset Prostate Cancer
por: Feichtinger, René G., et al.
Publicado: (2018)

Validation of Cell-Free RNA and Circulating Tumor Cells for Molecular Marker Analysis in Metastatic Prostate Cancer
por: Ladurner, Michael, et al.
Publicado: (2021)

Succinate Accumulation Is Associated with a Shift of Mitochondrial Respiratory Control and HIF-1α Upregulation in PTEN Negative Prostate Cancer Cells
por: Weber, Anja, et al.
Publicado: (2018)

Bcl-2 associated athanogene 5 (Bag5) is overexpressed in prostate cancer and inhibits ER-stress induced apoptosis
por: Bruchmann, Anja, et al.
Publicado: (2013)

Both IGF1R and INSR Knockdown Exert Antitumorigenic Effects in Prostate Cancer In Vitro and In Vivo
por: Ofer, Philipp, et al.
Publicado: (2015)

Novel therapeutic approaches for the treatment of castration-resistant prostate cancer()
por: Heidegger, Isabel, et al.
Publicado: (2013)

Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008
por: Oberaigner, Willi, et al.
Publicado: (2011)

Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis
por: Neuwirt, Hannes, et al.
Publicado: (2020)

Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer
por: Kafka, Mona, et al.
Publicado: (2020)

Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy
por: Santer, Frédéric R., et al.
Publicado: (2015)

Age-Adjusted PSA Levels in Prostate Cancer Prediction: Updated Results of the Tyrol Prostate Cancer Early Detection Program
por: Heidegger, Isabel, et al.
Publicado: (2015)

The Use of Dietary Supplements to Alleviate Androgen Deprivation Therapy Side Effects during Prostate Cancer Treatment
por: Dueregger, Andrea, et al.
Publicado: (2014)

Inhibition of Nox4‐dependent ROS signaling attenuates prostate fibroblast activation and abrogates stromal‐mediated protumorigenic interactions
por: Sampson, Natalie, et al.
Publicado: (2018)

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide
por: Hoefer, Julia, et al.
Publicado: (2016)

SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer
por: Hoefer, Julia, et al.
Publicado: (2014)

Akacid Medical Formulation Induces Apoptosis in Myeloid and Lymphatic Leukemic Cell Lines In Vitro and In Vivo
por: Neuwirt, Hannes, et al.
Publicado: (2015)

High Risk of Under-Grading and -Staging in Prostate Cancer Patients Eligible for Active Surveillance
por: Heidegger, Isabel, et al.
Publicado: (2015)

Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer
por: Puhr, Martin, et al.
Publicado: (2021)

Long-Term Treatment with Simvastatin Leads to Reduced Migration Capacity of Prostate Cancer Cells
por: Kafka, Mona, et al.
Publicado: (2022)

Putative Prostate Cancer Risk SNP in an Androgen Receptor‐Binding Site of the Melanophilin Gene Illustrates Enrichment of Risk SNPs in Androgen Receptor Target Sites
por: Bu, Huajie, et al.
Publicado: (2015)

Robo 4 - the double-edged sword in prostate cancer: impact on cancer cell aggressiveness and tumor vasculature
por: Pircher, Andreas, et al.
Publicado: (2019)

Characterization of Transcriptional Changes in ERG Rearrangement-Positive Prostate Cancer Identifies the Regulation of Metabolic Sensors Such as Neuropeptide Y
por: Massoner, Petra, et al.
Publicado: (2013)

Antidiabetic drugs influence molecular mechanisms in prostate cancer
por: Pircher, Andreas, et al.
Publicado: (2018)

Differential regulation of the androgen receptor by protein phosphatase regulatory subunits
por: Grey, James, et al.
Publicado: (2017)

Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer
por: Perner, Sven, et al.
Publicado: (2015)

Evaluation of the PI-RADS Scoring System for Classifying mpMRI Findings in Men with Suspicion of Prostate Cancer
por: Junker, Daniel, et al.
Publicado: (2013)

Validation of Next-Generation Sequencing of Entire Mitochondrial Genomes and the Diversity of Mitochondrial DNA Mutations in Oral Squamous Cell Carcinoma
por: Kloss-Brandstätter, Anita, et al.
Publicado: (2015)

PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer
por: Puhr, M, et al.
Publicado: (2016)

KDM5D predicts response to docetaxel chemotherapy in metastatic castration resistant prostate cancer patients
por: Schäfer, Georg, et al.
Publicado: (2021)

Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response
por: Kafka, Mona, et al.
Publicado: (2022)

p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer
por: Gruber, Martina, et al.
Publicado: (2020)

In Reply to ‘Do SGLT-2 Inhibitors Act Only Through a Functional Tubuloglomerular Feedback Induced by the Increased Outflow of Sodium?’
por: Neuwirt, Hannes, et al.
Publicado: (2020)

Potentials and Limitations of Real-Time Elastography for Prostate Cancer Detection: A Whole-Mount Step Section Analysis
por: Junker, Daniel, et al.
Publicado: (2012)

The Molecular Chaperone GRP78/BiP in the Development of Chemoresistance: Mechanism and Possible Treatment
por: Roller, Corinna, et al.
Publicado: (2013)

SEMMs: Somatically Engineered Mouse Models. A New Tool for In Vivo Disease Modeling for Basic and Translational Research
por: Lima, Anthony, et al.
Publicado: (2021)

Applications of CRISPR-Cas9 for advancing precision medicine in oncology: from target discovery to disease modeling
por: Ravichandran, Mirunalini, et al.
Publicado: (2023)

Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients
por: Steiner, Normann, et al.
Publicado: (2017)

Differential Utilization of Dietary Fatty Acids in Benign and Malignant Cells of the Prostate
por: Dueregger, Andrea, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ivgfg12irel7nrmods5rhgurai